<p><strong>Myelofibrosis (MF)</strong>: Ruxolitinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.<br />
<br />
<strong>Polycythaemia vera (PV)</strong>: Ruxolitinib is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.</p>